256 related articles for article (PubMed ID: 10588093)
41. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Takahara M; Shiraiwa T; Shindo M; Arai A; Kusuda Y; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
Hypertens Res; 2014 Sep; 37(9):852-7. PubMed ID: 24739538
[TBL] [Abstract][Full Text] [Related]
42. Candesartan cilexetil. A review of its use in essential hypertension.
McClellan KJ; Goa KL
Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
44. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
46. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
Raskin P; Guthrie R; Flack J; Reeves R; Saini R
J Hum Hypertens; 1999 Oct; 13(10):683-7. PubMed ID: 10516738
[TBL] [Abstract][Full Text] [Related]
47. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
48. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2004 May; 20(5):597-602. PubMed ID: 15140325
[TBL] [Abstract][Full Text] [Related]
49. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
Bönner G;
Blood Press Suppl; 2008 Dec; 2():22-30. PubMed ID: 19203019
[TBL] [Abstract][Full Text] [Related]
50. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
[TBL] [Abstract][Full Text] [Related]
51. [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Uen S; Un I; Fimmers R; Vetter H; Mengden T
Dtsch Med Wochenschr; 2007 Jan; 132(3):81-6. PubMed ID: 17219340
[TBL] [Abstract][Full Text] [Related]
52. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
Gradman AH; Lewin A; Bowling BT; Tonkon M; Deedwania PC; Kezer AE; Hardison JD; Cushing DJ; Michelson EL
Heart Dis; 1999; 1(2):52-7. PubMed ID: 11720604
[TBL] [Abstract][Full Text] [Related]
53. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
54. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.
Belcher G; Hübner R; George M; Elmfeldt D; Lunde H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S85-9. PubMed ID: 9331017
[TBL] [Abstract][Full Text] [Related]
55. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
Bakris G; Gradman A; Reif M; Wofford M; Munger M; Harris S; Vendetti J; Michelson EL; Wang R;
J Clin Hypertens (Greenwich); 2001; 3(1):16-21. PubMed ID: 11416677
[TBL] [Abstract][Full Text] [Related]
56. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
Lewin AJ; Weir MR
Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
[TBL] [Abstract][Full Text] [Related]
57. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Chrysant SG; Neutel JM; Ferdinand KC;
J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
[TBL] [Abstract][Full Text] [Related]
58. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Jan; 149 Suppl 4():172-81. PubMed ID: 18402243
[TBL] [Abstract][Full Text] [Related]
59. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Asmar R; Lacourcière Y
J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
[TBL] [Abstract][Full Text] [Related]
60. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
